Representing 18%-19% growth compared to first quarter 2024 revenue. The strong growth experienced in the first quarter of 2025 was driven by orthobiologics and licensing revenue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XTNT:
- Xtant Medical Faces Risk of Share Distribution by Major Stakeholder, Threatening Stock Stability
- Xtant Medical’s Earnings Call: Mixed Outlook with Growth Plans
- Xtant Medical price target lowered to $2 from $3 at BTIG
- Xtant Medical Reports Strong 2024 Revenue Growth
- XTNT Earnings this Week: How Will it Perform?